Answers are grounded in this paper and cite their sources.
This analysis demonstrates how FMI genomic profiling modifies treatment in patients with advanced NSCLC, suggesting improved outcomes.
Using FMI data, clinicians were able to direct patients toward clinical trials and to modify SOC clinical management for several NSCLC patients. These results demonstrate the benefit of FMI genomic profiling in identifying actionable driver mutations that would otherwise be missed by SOC methodology. The findings suggest that CGP is a promising and robust tool for improving personalized medicine in NSCLC treatment in Spain.
No takes yet. Share an insight, caveat, or question.
Rojo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: